DDInter392 DDInter1676
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Cladribine {u} (Compound) resembles {v} (Compound) Vidarabine
Cladribine {u} (Compound) resembles {v} (Compound) Nelarabine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Azacitidine
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abacavir
Cladribine {u} (Compound) treats {v} (Disease) hematologic cancer
Cladribine {u} (Compound) binds {v} (Gene) PNP
Cladribine {u} (Compound) upregulates {v} (Gene) RGS2
Cladribine {u} (Compound) downregulates {v} (Gene) PLK1
Cladribine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Reserpine
Cladribine (Compound) resembles Vidarabine (Compound)
Cladribine (Compound) resembles Nelarabine (Compound)
Cladribine may lead to a major life threatening interaction when taken with Azacitidine
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Cladribine (Compound) treats hematologic cancer (Disease)
Cladribine (Compound) binds PNP (Gene)
Cladribine (Compound) upregulates RGS2 (Gene)
Cladribine (Compound) downregulates PLK1 (Gene)
Cladribine (Compound) causes Cardiac disorder (Side Effect)
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Reserpine